NCT02468934

Brief Summary

The purpose of this study is to determine if electrical stimulation (small levels of electricity) can safely and effectively reduce pain following total knee replacement (or total knee arthroplasty (TKA)). This study involves a device called the SPRINT System. The SPRINT System delivers mild electrical stimulation to nerves in the leg that received the knee replacement. The SPRINT System includes a small wire (called a "lead") that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2015

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 22, 2015

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 11, 2015

Completed
4 months until next milestone

Study Start

First participant enrolled

October 22, 2015

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 17, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 17, 2017

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

September 4, 2018

Completed
Last Updated

September 4, 2018

Status Verified

August 1, 2018

Enrollment Period

1.7 years

First QC Date

April 22, 2015

Results QC Date

July 17, 2018

Last Update Submit

August 30, 2018

Conditions

Keywords

electrical stimulationneurostimulationneuromodulationTKA painpain following total knee replacementtotal knee arthroplasty

Outcome Measures

Primary Outcomes (2)

  • Average Knee Pain While Walking

    Subjects were asked to complete daily diaries to track their average pain intensity while walking during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average score for each diary period was calculated across subjects, and the mean scores for weeks 1-4 is reported.

    Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))

  • Number of Participants That Experienced at Least One Study-Related Adverse Event

    At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition has occurred since their previous visit. If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site. The number of subjects that experienced at least one study-related adverse event is reported here.

    Total of 21 months (from when the first subjects enrolled to when the last subject completed the study)

Secondary Outcomes (14)

  • Average Knee Pain Over the Last 24 Hours

    Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))

  • Average Knee Pain at Rest

    Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))

  • Amount of Analgesic Usage

    Visit 4 (Day of Surgery) and Visits 6-11 (weeks 1-6 post-Total Knee Arthroplasty (TKA))

  • Number of Participants That Experienced at Least One Opioid-Related Side Effect

    Visit 1 (Baseline), Visit 2 (Lead Placement), Visits 5-13 (in-hospital days through 3-months post-Total Knee Arthroplasty (TKA))

  • Time to Achieve 90 Degrees Flexion in Affected Knee

    Visit 2 (Lead Placement), Visit 7 (3-weeks Post-Total Knee Arthroplasty (TKA)), Visit 11 (6-weeks Post-TKA), Visit 13 (3-months Post-TKA)

  • +9 more secondary outcomes

Study Arms (1)

Peripheral Nerve Stimulation

EXPERIMENTAL

All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.

Device: SPRINT Peripheral Nerve Stimulation (PNS) System

Interventions

The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a "Lead") that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).

Also known as: Smartpatch, Smartpatch System, SPRINT System
Peripheral Nerve Stimulation

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 21 years old
  • Scheduled to undergo a primary unilateral total knee replacement procedure

You may not qualify if:

  • Body Mass Index (BMI) \> 40 kg/m2
  • Compromised immune system based on medical history
  • History of valvular heart disease
  • Implanted electronic device
  • Joint or overlying skin infection of the affected limb
  • History of recurrent skin infections
  • Bleeding disorder
  • Allergy to skin surface electrodes and/or medical-grade adhesive tapes
  • Pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

University of California San Diego

La Jolla, California, 92037, United States

Location

Duke University Medical Center

Durham, North Carolina, 22710, United States

Location

Joint Implant Surgeons

New Albany, Ohio, 43054, United States

Location

MeSH Terms

Conditions

PainPain, PostoperativeMusculoskeletal Diseases

Interventions

Drug Delivery Systems

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic Processes

Intervention Hierarchy (Ancestors)

Drug TherapyTherapeutics

Results Point of Contact

Title
Clinical Affairs
Organization
SPR Therapeautics

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 22, 2015

First Posted

June 11, 2015

Study Start

October 22, 2015

Primary Completion

July 17, 2017

Study Completion

July 17, 2017

Last Updated

September 4, 2018

Results First Posted

September 4, 2018

Record last verified: 2018-08

Locations